Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ziyan Yang, Nani Li, Xiaolin Li, Lei Lei & Xiaojia Wang. (2020) The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients. OncoTargets and Therapy 13, pages 853-863.
Read now
Read now
Andria Hadjipanteli, Paul Doolan, Efthyvoulos Kyriacou & Anastasia Constantinidou. (2020) Breast Cancer Brain Metastasis: The Potential Role of MRI Beyond Current Clinical Applications. Cancer Management and Research 12, pages 9953-9964.
Read now
Read now
Articles from other publishers (12)
E. S. Grigoryeva, L. A.Tashireva, V. V. Alifanov, O. E. Savelieva, S. V. Vtorushin, M. V. Zavyalova, O. D. Bragina, E. Y. Garbukov, N. V. Cherdyntseva, E. L. Choinzonov & V. M. Perelmuter. (2022) Molecular subtype conversion in CTCs as indicator of treatment adequacy associated with metastasis-free survival in breast cancer. Scientific Reports 12:1.
Crossref
Crossref
G. A. Panshin & N. V. Nudnov. (2022) Magnetic resonance imaging in the diagnosis of breast cancer metastases in the brain (a brief review of the literature). Medical Visualization 26:4, pages 23-31.
Crossref
Crossref
O. D. Bragina, V. I. Chernov, S. M. Deyev & V. M. Tolmachev. (2022) Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins. Bulletin of Siberian Medicine 21:3, pages 132-139.
Crossref
Crossref
Olga D. Bragina, Sergei M. Deyev, Vladimir I. Chernov & Vladimir M. Tolmachev. (2022) The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer. Acta Naturae 14:2, pages 4-15.
Crossref
Crossref
Elena Díaz-Rodríguez, Lucía Gandullo-Sánchez, Alberto Ocaña & Atanasio Pandiella. (2021) Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers 14:1, pages 154.
Crossref
Crossref
Yu. S. Krumin, V. A. Khaylenko, N. A. Kozlov, G. Yu. Cheremis, A. V. Petrovskyy, D. V. Khaylenko, E. V. Artamonova & E. I. Kovalenko. (2021) Clinical significance of changes in the expression level of markers of surrogate breast cancer subtypes in recurrent and metastatic foci (literature review). Tumors of female reproductive system 16:4, pages 41-45.
Crossref
Crossref
Manikandan Dhanushkodi & Shirley Sundersingh. (2019) HER2 Loss in Advanced Breast Cancer: Durable Response to Fulvestrant and Palbociclib. Indian Journal of Gynecologic Oncology 18:1.
Crossref
Crossref
K.V. Konyshev & S.V. Sazonov. (2020) Changes in expression of immunohistochemical markers in regional breast cancer metastases. Arkhiv patologii 82:4, pages 19.
Crossref
Crossref
Manikandan Dhanushkodi, Shirley Sundersingh & Arvind Krishnamurthy. (2019) Oesophageal Metastasis from Breast Cancer: Mimicker of Primary Oesophageal Cancer. Indian Journal of Gynecologic Oncology 17:4.
Crossref
Crossref
Chao Li, Hongwei Fan, Qian Xiang, Ling Xu, Zhuo Zhang, Qianxin Liu, Tongtong Zhang, Jinjie Ling, Ying Zhou, Xia Zhao & Yimin Cui. (2019) Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis. Breast Cancer Research and Treatment 178:3, pages 497-504.
Crossref
Crossref
Akira Matsui, Yuya Murata, Norikazu Masuda, Kiyoshi Mori, Masato Takahashi, Katsushige Yamashiro, Kenjirou Aogi, Shigeto Maeda, Masahiro Itou, Shinji Ozaki, Kazuya Kuraoka, Yasuyuki Satou, Shu Ichihara, Eriko Tokunaga, Kenichi Taguchi, Takanori Watanabe, Hiroyoshi Suzuki, Aiko Nagayama & Rieko Nishimura. (2019) Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional study. Oncotarget 10:55, pages 5680-5689.
Crossref
Crossref
I. V. Kolyadina, Yu. Yu. Andreeva, G. A. Frank & I. V. Poddubnaya. (2018) Role of biological heterogeneity in recurrent and metastatic breast cancer. Arkhiv patologii 80:6, pages 62.
Crossref
Crossref